<DOC>
	<DOCNO>NCT02688270</DOCNO>
	<brief_summary>The purpose study determine ability Vascana ( 0.9 % nitroglycerin topical cream ) treat prevent symptom experience subject 's Raynaud 's Phenomenon . The symptoms disease include pain , tingling , numbness finger affect hand hand .</brief_summary>
	<brief_title>Efficacy Safety VascanaÂ® Subjects With Secondary Raynaud 's Phenomenon</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<mesh_term>Nitroglycerin</mesh_term>
	<criteria>1 . Provide write consent prior studyspecific evaluation 2 . Males female age 18 year 75 year , inclusive 3 . A clinical diagnosis secondary Raynaud 's Phenomenon ( define Raynaud 's Phenomenon ( RP ) significant enough cause patient modify daily behavior ) determine history cold sensitivity pain , numbness , and/or tingle along pallor cyanosis finger , event observe study physician diagnosis disease state know associated RP . Secondary RP may due scleroderma , systemic lupus erythematosus , mixed connective tissue disease , connective tissue diseases 4 . Agree apply study drug finger specify protocol 5 . Agree control cold exposure describe protocol 6 . Willing discontinue current vasodilator therapy use specifically treatment Raynaud 's 7 . Agree use investigational medication approve unapproved therapy treat RP symptom participate study . Such medication include , limited : dosage form nitroglycerin , eg , isosorbide dinitrate , fenoldopam mesylate , milrinone lactate , nifedipine , diltiazem , felodipine , nimodipine , nisoldipine , fluoxetine , pregabalin , verapamil . Use phosphodiesterase 5 inhibitor ( eg , sildenafil , tadalafil , vardenafil ) exclude unless use intermittently male erectile dysfunction take within 48 hour schedule study drug dose 8 . Negative urine pregnancy test woman childbearing potential prior first study treatment agree use effective contraception throughout study 9 . Able comply study requirement 1 . Past history RP attack sufficient severity require inpatient hospitalization 2 . Presence active digital ulcer define painful ulcer visible depth loss epithelialization . Ulcers cover eschar wherein depth epithelialization judge say `` indeterminant '' exclusionary . 3 . Raynaud 's Phenomenon secondary nonconnective tissue disorder include thromboangiitis obliterans ( Buerger 's disease ) , hemorheologic disorder , major arterial occlusive disease , past exposure vasopathic agent ( include vinblastine , ci platinum , bleomycin ) , ongoing therapy vasoconstrictive agent ( eg , betablockers ) , past frostbite injury amongst others . Subjects hepatitis C also exclude . 4 . Patients diagnose pulmonary arterial hypertension require specific therapy . 5 . Concurrently use nitrate medication medication know interact nitroglycerin sildenafil , treatment erectile dysfunction beyond screen . Subjects may participate study drug discontinue least 5 halflives 6 . Concurrently use medication device might interfere study medication ( include RP therapy , drug use hypertension , arrhythmia , depression , pain ) , specifically calcium channel blocker compound list prohibit concomitant medication beyond screening , unless medication require condition Raynaud 's . Subjects may participate study drug discontinue least 5 halflives . 7 . Known allergy nitroglycerin common topical cream ingredient 8 . History migraine , cluster , vascular headache , chronic pain ( define pain 3hour duration longer daily basis ) great intensity pain associate RP chronic pain condition finger 9 . Any unstable medical problem current medical condition , judgment investigator , would contraindicate administration study medication , interfere study evaluation , interfere subject 's ability comply study protocol 10 . Cognitive language difficulty would impair completion symptom assessment instrument 11 . Within past 3 month , myocardial infarction , uncontrolled congestive heart failure , unstable angina , uncontrolled hypotension , uncontrolled hypertension ( defined subject treat medically control condition ) 12 . Participated study investigational drug within 4 week prior visit 1 13 . Screening laboratory value 20 % upper low limit normal consider clinically significant investigator 14 . Had major abdominal , thoracic , vascular surgery within 6 month visit 1 15 . Pregnant nursing woman 16 . Women childbearing potential unable unwilling comply contraceptive requirement study period 17 . History relevant drug and/or food allergy result systemic reaction require medical treatment 18 . History alcohol abuse drug addiction estimation principal investigator would affect subject ability participate study 19 . Consumption alcohol day visit day visit . 20 . Consumption two alcoholic beverage daily basis . 21 . Use tobacco product type level precede 6 month duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>